Market Overview

Goldman Sachs Downgrades Myriad Genetics, Inc. to Neutral, Lowers PT to $26.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for MYGN

DateFirmActionFromTo
Jan 2016Deutsche BankInitiates Coverage onBuy
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform
Dec 2015Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (MYGN)

Get Benzinga's Newsletters